MRKV-171 is under clinical development by Merck & Co and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect MRKV-171’s likelihood of approval (LoA) and phase transition for Respiratory Syncytial Virus (RSV) Infections took place on 28 May 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their MRKV-171 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

MRKV-171 overview

MRK-V171 (MRK-1777) is under development for the prevention of respiratory syncytial virus infections. The drug candidate is developed by using messenger RNA therapeutic platform, which enables the body to produce its own healing proteins. This technology enables messenger RNA to elude the body’s innate immune response.

Merck & Co overview

Merck & Co (Merck) is a biopharmaceutical company focused on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines and animal health products. It offers prescription products for therapy areas related to cardiovascular, cancer, immune disorders, infectious, respiratory and women’s diseases, and diabetes. The company provides animal health products such as vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.

Quick View MRKV-171 LOA Data

Report Segments
  • Innovator
Drug Name
  • MRKV-171
Administration Pathway
Therapeutic Areas
  • Infectious Disease
Key Developers
  • Sponsor Company: Merck & Co
  • Originator: Valera and Merck & Co
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.